Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience

Table 1 Calculation of relative risk

	Sokal score	Hasford score	EUTOS
Calculation	0.0116 × (age - 43.4) + 0.0345 × (spleen - 7.51) + 0.188 × [(platelet count/700)2 - 0.563] + 0.0887 × (blast cells - 2.10)	0.666 when age ≥ 50 + (0.042 × spleen) + 1.0956 when platelet > 1500 × 109/L + (0.0584 × blast cells) + 0.20399 when basophils > 3% + (0.0413 × eosinophils) + 100	Spleen × 4 + basophils × 7
Risk definition	Exponential of the total	Total × 1000	Total
	Low risk: < 0.8	Low risk: ≤ 780	Low risk: ≤ 87
	Intermediate risk: 0.8-1.2	Intermediate risk: 781-1480	High risk: > 87
	High risk: > 1.2	High risk: > 1480

Age is given in years. Spleen is given in centimeters below the costal margin (maximum distance). Blast cells, eosinophils, and basophils are given in percent of peripheral blood differential. All values must be collected before any treatment. EUTOS: European Treatment and Outcome Study.

Table 2 European LeukemiaNet response criteria to tyrosine kinase inhibitors at first line

	Optimal	Warning	Failure
Baseline	NA	High risk or CCA/Ph+, major route	NA
3 mo	BCR-ABL1 ≤ 10% and/or Ph+ ≤ 35%	BCR-ABL1 > 10% and/or Ph+ 35%-95%	Non-CHR and/or Ph+ > 95%
6 mo	BCR-ABL1 ≤ 1% and/or Ph+ 0	BCR-ABL1 1%-10% and/or Ph+ 1%-35%	BCR-ABL1 > 10% and/or Ph+ > 35%
12 mo	BCR-ABL1 ≤ 0.1%	BCR-ABL1 > 0.1%-1%	BCR-ABL1 > 1% and/or Ph+ > 0
Then, and any at time	BCR-ABL1 ≤ 0.1%	CCA/Ph- (-7 or 7q-)	Loss of CHR Loss of CCyR Confirmed loss of MMR mutations CCA/Ph+

In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level ≥ 1%. This table was originally published in Baccarani et al[5]. CCA/Ph⁺: Clonal cytogenetic abnormalities in Ph-positive cells; CCA/Ph^-: Clonal cytogenetic abnormalities in Ph-negative cells; Ph: Philadelphia chromosome; CCyR: Complete cytogenetic response; MMR: Major molecular response; NA: Not applicable.

Table 3 Patients characteristics

Patient	Sex	Age at ASCT (yr)	Disease phase at ASCT	Time from diagnosis to ASCT (mo)	Indication for ASCT	Donor sex
1	M	22	1st AP	50	Resistance to imatinib and clonal evolution	M
2	F	51	2nd CP	14	Previous myeloid blastic phase	M
3	M	25	2nd CP	61	Previous lymphoid blastic phase	M
4	M	33	1st CP	37	Resistance to imatinib and dasatinib	M
5	F	54	1st AP	103	Resistance to imatinib, nilotinib and dasatinib 1st accelerated phase	F
6	M	65	1st CP	133	Resistance to imatinib and nilotinib	F
7	F	49	1st CP	62	Resistance to imatinib	M
8	M	53	2nd CP	63	Previous myeloid blastic phase	M
9	M	41	1st CP	51	Resistance to imatinib	M
10	M	61	1st CP	75	Resistance to imatinib, nilotinib and dasatinib	F

ASCT: Allogeneic stem cell transplantation; AP: Accelerated phase; CP: Chronic phase; M: Male; F: Female.

Table 4 Transplantation outcomes

Patient	PNL engraftment (d)	PLT engraftment (d)	Acute GVHD	Chronic GVHD	Post-transplant disease status	Last status
1	12	18	No	No	Molecular relapse and granulocytic sarcoma	Died
2	15	16	No	No	Blastic crises	Died
3	18	30	No	No	Remission	Died
4	14	14	Yes	No	Remission	Died
5	25	21	Yes	Yes	Remission	Alive
6	19	15	Yes	No	Remission	Died
7	10	10	No	No	Remission	Alive
8	10	10	Yes	No	Remission	Died
9	11	14	Yes	No	Remission	Alive
10	12	13	Yes	No	Remission	Died

GVHD: Graft vs host disease; PNL: Neutrophil; PLT: Platelet.